Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma - Prognostic and therapeutic implications
Autore:
Giatromanolaki, A; Sivridis, E; Brekken, R; Thorpe, PE; Anastasiadis, P; Gatter, KC; Harris, AL; Koukourakis, MI;
Indirizzi:
Democritus Univ Thrace, Dept Pathol, Alexandroupolis, Greece Democritus Univ Thrace Alexandroupolis Greece , Alexandroupolis, Greece Democritus Univ Thrace, Dept Obstet & Gynecol, Alexandroupolis, Greece Democritus Univ Thrace Alexandroupolis Greece , Alexandroupolis, Greece Democritus Univ Thrace, Dept Radiotherapy & Oncol, Alexandroupolis, GreeceDemocritus Univ Thrace Alexandroupolis Greece , Alexandroupolis, Greece Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA Univ Texas Dallas TX USA 75235 Ctr, Dept Pharmacol, Dallas, TX 75235 USA John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England John Radcliffe Hosp Oxford England OX3 9DU Sci, Oxford OX3 9DU, England John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Mol Oncol Labs,Oxford OX3 9DU, England John Radcliffe Hosp Oxford England OX3 9DU Labs,Oxford OX3 9DU, England
Titolo Testata:
CANCER
fascicolo: 10, volume: 92, anno: 2001,
pagine: 2569 - 2577
SICI:
0008-543X(20011115)92:10<2569:TA"EGF>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL LUNG-CANCER; THYMIDINE PHOSPHORYLASE; FACTOR EXPRESSION; TYROSINE KINASE; VEGF; IDENTIFICATION; LOCALIZATION; INDICATOR; P53;
Keywords:
endometrial carcinoma; vascular endothelial growth factor; VEGF/KDR; angiogenesis; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Giatromanolaki, A Tumour & Angiogenesis Res Grp, 18 Dimokratias Ave, Iraklion 71306, Greece Tumour & Angiogenesis Res Grp 18 Dimokratias Ave Iraklion Greece 71306
Citazione:
A. Giatromanolaki et al., "The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma - Prognostic and therapeutic implications", CANCER, 92(10), 2001, pp. 2569-2577

Abstract

BACKGROUND. Vascular endothelial growth factor (VEGF) is an important endothelial cell mitogen associated with increased angiogenesis and aggressive tumor behavior, Its stimulating effect on endothelial cells basically is dependent on the presence of specific VEGF receptors, such as the flk-1(KDR) receptor. This study investigates the roles of VEGF and of a functionally intact angiogenic pathway "VEGF/flk-1 (KDR)," in patients with endometrial carcinoma and their significance in prognosis and therapy. METHODS. A series of 121 endometrial carcinomas were studied. The expression of VEGF by endometrial tumor cells was assessed using the monoclonal antibody (MoAb) VG1. VEGF/KDR complexes on tumor endothelium or activated microvessel density (aMVD) were identified using the MoAb 11B5. In addition, the standard microvessel density (sMVD) was assessed with anti-CD31. In all tumors, the alkaline phosphatase/antialkaline phosphatase technique was employed. A Fisher exact test or an unpaired, two-tailed t test was used for testing correlations between categoric tumor variables, whereas a log-rank test was used to determine statistical differences between life tables. A Coxproportional hazards model was used to assess the effect of tumor variables on overall survival. RESULTS. Cytoplasmic VEGF expression in > 50% of tumor cells was associated significantly with aMVD (P < 0.0001) and with sMVD (P < 0.003). In univariate survival analysis, VEGF (P = 0.0002), aMVD (P = 0.001), and sMVD (P = 0.0009) were significant prognostic variables. Equally important were the histologic parameters tumor type (P = 0.03), tumor grade (P = 0.003), and disease stage (P < 0.0001). In multivariate analysis, disease stage was the most important independent prognostic factor (P < 0.0001), followed by VEGF/KDR (P < 0.01), and VEGF (P < 0.04). Furthermore, VEGF and VEGF/KDR were the only independent prognostic variables for patients with Stage I endometrioid adenocarcinoma. CONCLUSIONS. sMVD and the angiogenic factor VEGF are important indicators of a poor prognosis in patients with endometrial carcinoma. VEGF/KDR complexes define a subgroup of patients with endometrial carcinoma with an even worse prognosis. (C) 2001 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/06/20 alle ore 23:51:08